Between 2010 and 2020, drug companies across the world spent more than £1.2trillion trying to find new ways to cure diseases.
Much of that money was devoted to seeking treatments for cancer, diabetes, heart problems and other increasingly widespread conditions of the modern age.
Now, however, attention is turning to another area, infectious diseases. Many of these have been out of fashion in the research and development world, but the Covid19 pandemic has highlighted the devastation they can cause.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.